BOOTS UK LIMITED
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Drugs, Drug Proprietaries, and Druggists' Sundries, Miscellaneous General Merchandise Stores, Drug Stores and Proprietary Stores), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about BOOTS UK LIMITED
Live alerts from global media, monitored by Business Radar
2022-08-26 (chemistanddruggist.co.uk)
Boots hit with £111m post-tax losses in 2020/21, report reveals
Boots reported a £111 million post-tax loss for the financial year ending August 2021, despite its Boots.com sales more than doubling in the same period , its most recent financial statements have revealed.
Read more
2022-08-26 (chemistanddruggist.co.uk)
Boots hit with £111m post-tax losses in 2020/21, report reveals
Boots reported a £111 million post-tax loss for the financial year ending August 2021, despite its Boots.com sales more than doubling in the same period , its most recent financial statements have revealed.
Read more
2020-05-21 (insidermedia.com)
Pre-tax profits continue to slide at Boots
Pre-tax profits dropped by more than £180m at Boots UK during its latest financial year, new documents have revealed.
Read more
2020-05-21 (insidermedia.com)
Pre-tax profits continue to slide at Boots
Pre-tax profits dropped by more than £180m at Boots UK during its latest financial year, new documents have revealed.
Read more
2014-07-19 (forbes.com)
Can Anything Stop Drug Companies From Fleeing The U.S. Tax System?
Friday morning, after five spurned bids, AbbVie, the North Chicago-based pharmaceutical giant finally closed in on a deal to buy Irish drugmaker Shire for $54 billion. One key consequence of the deal: AbbVie will change its tax domicile from Illinois to the U.K., reducing its tax rate. The deal, the largest [...]
Read more
2014-07-19 (forbes.com)
Can Anything Stop Drug Companies From Fleeing The U.S. Tax System?
Friday morning, after five spurned bids, AbbVie, the North Chicago-based pharmaceutical giant finally closed in on a deal to buy Irish drugmaker Shire for $54 billion. One key consequence of the deal: AbbVie will change its tax domicile from Illinois to the U.K., reducing its tax rate. The deal, the largest [...]
Read more